Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma

Parejo-Alonso, B., Royo-García, A., Espiau-Romera, P., Courtois, S., Curiel-García, Á., Zagorac, S., Villaoslada, I., Olive, K. P., Heeschen, C., & Sancho, P. (2023). Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Biomedicine & Pharmacotherapy, 158, 114162. https://doi.org/10.1016/j.biopha.2022.114162
Authors:
Beatriz Parejo-Alonso
Alba Royo-García
Pilar Espiau-Romera
Sarah Courtois
Álvaro Curiel‐García
Sladjana Zagorac
Isabel Villaoslada
Kenneth P. Olive
Christopher Heeschen
Patricia Sancho
Affiliated Authors:
Álvaro Curiel‐García
Kenneth P. Olive
Author Keywords:
pancreatic ductal adenocarcinoma
alk
receptor tyrosine kinases
cancer stem cells
chemoresistance
Publication Type:
Article
Unique ID:
10.1016/j.biopha.2022.114162
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: